

1.69-2.97). After adjusting for age, gender, BMI, history of diseases, hsCRP, LDLc, TMAO levels remained associated with frailty (OR=2.11, 95%CI, 1.01-4.38). Similarly, a cubic spline curve showed a dose-dependent relationship between the odds ratio for the risk of frailty and circulating TMAO in a linear trend ($p = 0.006$). This study suggests that circulating TMAO are independently associated with frailty in older adult with cardiovascular diseases. Efforts to further characterize the relationship between gut microbiota metabolite and frailty should be further pursued.

ASSOCIATION OF BRAIN NATRIURETIC PEPTIDE WITH MORTALITY IN EXCEPTIONALLY LONG-LIVED FAMILIES

Allison Kuipers,¹ Robert Boudreau,¹ Mary Feitosa,² Angeline Galvin,³ Bharat Thygarajan,⁴ and Joseph Zmuda,¹
 1. *University of Pittsburgh, Pittsburgh, Pennsylvania, United States*, 2. *Washington University School of Medicine, St Louis, Missouri, United States*,
 3. *University of Southern Denmark, Odense C, Midtjylland, Denmark*, 4. *University of Minnesota, Minneapolis, Minnesota, United States*

Natriuretic peptides are produced within the heart and released in response to increased chamber wall tension and heart failure (HF). N-Terminal prohormone Brain Natriuretic Peptide (NT-proBNP) is a specific natriuretic peptide commonly assayed in persons at risk for HF. In these individuals, NT-proBNP is associated with future disease prognosis and mortality. However, its association with mortality among healthy older adults remains unknown. Therefore, we determined the association of NT-proBNP with all-cause mortality over a median follow-up of 10 years in 3253 individuals free from HF at baseline in the Long Life Family Study, a study of families recruited for exceptional longevity. We performed cox proportional hazards analysis (coxme in R) for time-to-event (mortality), adjusted for field center, familial relatedness, age, sex, education, smoking, alcohol, physical activity, BMI, diabetes, hypertension, and cancer. In addition, we performed secondary analyses among individuals (N=2457) within the normal NT-proBNP limits at baseline (<125pg/ml aged <75 years; <450pg/ml aged ≥75 years). Overall, individuals were aged 32-110 years (median 67 years; 44% male), had mean NT-proBNP of 318.5 pg/ml (median 91.0 pg/ml) and 1066 individuals (33%) died over the follow-up period. After adjustment, each 1 SD greater baseline NT-proBNP was associated with a 1.30-times increased hazard of mortality (95% CI: 1.24-1.36; $P < 0.0001$). Results were similar in individuals with normal baseline NT-proBNP (HR: 1.21; 95% CI: 1.11-1.32; $P < 0.0001$). These results suggest that NT-proBNP is a strong and specific biomarker for mortality in older adults independent of current health status, even in those with clinically-defined normal NT-proBNP.

EXAMINING ANKLE FOOT ORTHOSIS WEAR TIME IN PATIENTS WITH PERIPHERAL ARTERY DISEASE

Sara Myers,¹ Danae Dinkel,¹ Mahdi Hassan,² Holly Despiegelaere,³ Jason Johanning,⁴ and Iraklis Pipinos,⁴
 1. *University of Nebraska at Omaha, Omaha, Nebraska, United States*, 2. *University of Nebraska Omaha, Omaha, Nebraska, United States*, 3. *VA Medical*

Center, Omaha, United States, 4. *University of Nebraska Medical Center, Omaha, Nebraska, United States*

Peripheral artery disease (PAD) impacts over 8.5 million Americans and the prevalence of PAD increases with age. PAD restricts blood flow to the leg and its most common manifestation is claudication, a severe impairment of walking produced by ischemia-related, leg pain during exercise. An ankle foot orthosis (AFO) could improve these symptoms. To understand the potential impact of AFO usage, it is critical to determine wearability of the device in patients with PAD. The purpose of this study was to monitor wear time of an AFO and explore perceptions of the device. Participants (n=14) with PAD and claudication wore an AFO for three months. An accelerometer was placed directly on the AFO for 7 days and participants completed semi-structured interviews at midpoint (1.5 months) and post intervention (3 months). Based on accelerometer data at midpoint participants wore the AFO for an average of 4.9±2.3 out of 7 days and for an average of 7.5±4.2 hours each day. At post, participants wore the AFO for an average of 4.8±2.2 days for an average of 7.4±4.6 hours per day. In the interviews, almost all participants noted multiple barriers to wearing the AFO such as difficulty putting the AFO on and off, using stairs, walking on uneven ground, and driving. Our study found that participants wore the AFO ~7 hours/day but experienced barriers which may have limited their wear outside of these monitoring periods suggesting patients would wear an assistive device if design could be improved to address barriers.

IDEAL CARDIOVASCULAR HEALTH IS ASSOCIATED WITH SLOWNESS AMONG COMMUNITY-DWELLING OLDER ADULTS

Heeun Jung,¹ Miji Kim,² Hayoung Shim,³ Yuri Seo,¹ Seoyoon Jane Lee,⁴ and Chang Won Won,⁵
 1. *Graduate School, Kyung Hee University, Seoul, Republic of Korea*,
 2. *College of Medicine, Kyung Hee University, Seoul, Republic of Korea*, 3. *Kyung Hee University, Seoul, Korea, Seoul, Republic of Korea*, 4. *Elderly Frailty Research Center, Kyung Hee University, Seoul, Republic of Korea*, 5. *Kyung Hee University Medical Center, Seoul, Korea, Seoul, Republic of Korea*

Slowness is associated with increased disability and mortality in older people. However, the relation between ideal cardiovascular health (CVH) and slowness in community-dwelling older adults is uncertain. We examined the prevalence of ideal CVH in Korean older adults and its association with slowness in community-dwelling older adults. We analyzed 2,597 participants (mean age 76.0±3.9 years, 54.4% women) without cardiovascular disease from the Korean Frailty and Aging Cohort Study. The usual gait speed over a distance of 4 m was measured using an automatic timer, and slowness was defined as a speed <1.0 m/s. Ideal CVH was described as attainment of ideal health behaviors (no smoking, regular physical activity, ideal body mass index, and healthy diet) and optimal health factors (blood pressure, HDL-cholesterol, and glycated hemoglobin). Multiple logistic regression analysis was used to examine the association between the CVH score and slowness. Ideal CVH was present in 785(30.2%) subjects. Considering those with poor level of CVH were as the reference group, the odds ratios

[OR] for slowness were 0.55 (95% confidence interval [CI], 0.39-0.77) for those with intermediate level of CVH, and 0.28 (95% CI, 0.17-0.45) for those with ideal level of CVH after adjustment for potential confounders. Among ideal CVH components, behavioral CVH score (OR 0.65, 95% CI 0.58-0.74) was significantly associated with slowness vs. the biological CVH score (OR 0.95, 95% CI 0.84-1.07). This study indicates that ideal CVH is significantly associated with a lower risk of slowness in community-dwelling older adults. A better CVH may help prevent slowness.

INVESTIGATION OF ROLL-OVER CHARACTERISTICS IN HEALTHY OLD INDIVIDUALS AND PATIENTS WITH PERIPHERAL ARTERY DISEASE

Sara Myers,¹ Ganesh Bapat,¹ Jason Johanning,² and Iraklis Pipinos,² 1. *University of Nebraska at Omaha, Omaha, Nebraska, United States*, 2. *University of Nebraska Medical Center, Omaha, Nebraska, United States*

Atherosclerotic blockages in the leg arteries, cause leg pain with ambulation (called claudication), impair gait and substantially reduce the walking ability of patients with peripheral artery disease (PAD). Ankle-foot orthoses are being developed and applied so patients can walk more and with less pain. Roll-over shape (ROS) is a potential design objective for such assistive devices. In the proposed work, we study roll-over characteristics in patients with PAD and healthy older subjects. Gait data of ten healthy older individuals (Age: 72.8 ± 5.5 years) and twenty patients with PAD (Age: 64.1 ± 6.6 years) were collected at self-selected walking speed. In patients with PAD, gait data were collected before the onset of pain and after claudication pain was induced. To generate ROS, the center of pressure data was transferred to the shank-based coordinate system and circular arcs were fit using an optimization program in MATLAB. Independent t-tests with Bonferroni corrections were used to separately compare roll-over radius differences (p<0.05) between healthy older to both walking conditions in patients with PAD. The mean roll-over radius was not significantly different between healthy older vs PAD pain-free (p=0.468) or PAD pain-induced (p=0.289) walking conditions. Our results indicate invariance of ROS radius in patients with PAD, which is consistent with previous literature showing general invariance of ROS in healthy young individuals. Previous biomechanical studies show gait kinematics and kinetics are more affected by PAD than by age. Future studies should focus on the potential adaptive mechanisms in patients with PAD achieving invariant ROS.

LONG LIFE FAMILY STUDY SHOWS REDUCED CORONARY ARTERY DISEASE DESPITE HIGH POLYGENIC HAZARD SCORES

Mary Feitosa,¹ Allison Kuipers,² Mary Wojczynski,¹ Lihua Wang,¹ Thomas Perls,³ Kaare Christensen,⁴ Joseph Zmuda,² and Michael Province,⁵ 1. *Washington University School of Medicine, St Louis, Missouri, United States*, 2. *University of Pittsburgh, Pittsburgh, Pennsylvania, United States*, 3. *Boston University School of Medicine, Boston, Massachusetts, United States*, 4. *University of Southern Denmark, Odense C, Syddanmark, Denmark*, 5. *Washington University School of Medicine, SAINT LOUIS, Missouri, United States*

Polygenic hazard scores (PHS) for coronary artery disease (CAD) quantify individuals with age-specific genetic risk for CAD. We evaluated how well the PHS predict age at onset of CAD in the Long Life Family Study (LLFS; families selected for exceptional longevity), compared to the Family Heart Study (FamHS; random families and high CAD-risk families). LLFS contains 4572 European ancestry (EA) individuals from 581 families (age: 74.0 ± 14.3, range: 22-110 years). FamHS Random has 1806 EA individuals from 454 families (age: 56.2 ± 13.5, range: 22-91 years), while FamHS High CAD-risk has 2301 EA individuals from 553 families (age: 53.2 ± 12.8, range: 21-93 years). We generated the PHS from 176 published SNPs from GWAS for CAD (p < 5.0 × 10⁻⁸, r² < 0.2). In each of the extremes of the CAD PHS distributions (75%), Kaplan-Meier method showed that the LLFS presented significant delayed age at onset of CAD compared to FamHS (random and High CAD-risk: P < 0.0001). A Cox proportional hazards regression model accounting for CAD age at onset, using family bootstrap (N = 1000) to correct for family relatedness, replicated these results. For example, in the top-25% CAD-PHS when comparing to FamHS high-risk, the LLFS CAD hazards ratio was 0.127 (95% CI: 0.099, 0.164). Our findings suggest that, while PHS captured some of the risk of CAD in LLFS, part of the predisposition remains to be determined. Other relevant factors, including additional genetic discoveries and lifestyle-environment influences are needed to fully determine CAD risk in extreme samples.

SYSTEMATIC REVIEW OF GUIDELINES ON ANTIHYPERTENSIVE TREATMENT IN OLDER ADULTS: SPRINTING TO MORE HETEROGENEITY?

Jonathan Bogaerts,¹ Leonie von Ballmoos,² Wilco Achterberg,¹ Jacobijn Gussekloo,¹ Sven Streit,² Milly van der Ploeg,³ Yvonne Drewes,¹ and Rosalinde Poortvliet,¹ 1. *Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands*, 2. *University of Bern, Bern, Bern, Switzerland*, 3. *Leiden University, Leiden, The Hague, Netherlands*

Clinical trials have demonstrated that antihypertensive treatment (AHT) in older adults is beneficial. Longitudinal studies, in contrast, have shown that low blood pressure is associated with higher all-cause mortality, especially in frail older adults. Despite the high quality of the available evidence, its translation into clinical guidance for the heterogeneous older population is challenging. To give a systematic overview of blood pressure targets for older adults recommended in clinical guidelines, we searched PubMed, Embase, Emcare, and five guideline databases. We selected guidelines with numerical thresholds for the initiation or the goal of non-disease-specific AHT (January 2008-October 2019). Guidelines with advices concerning AHT in older adults were analyzed. We appraised the guideline quality with the AGREEII-instrument. Of the 44 guidelines containing a numerical threshold for the initiation or the goal of AHT, 33 (75%) provided recommendations concerning AHT for older adults. Nineteen advised a higher target of systolic blood pressure (SBP) for older adults in comparison with the middle-aged population and 3 more recent advised a lower target. Over half (19/33) recommended to treat hypertension in the oldest old to a SBP <150 mmHg, while others